Differential inhibition of cyclooxygenase-1 (COX-1) and-2 (COX-2) by NSAIDS: Consequences on anti-inflammatory activity versus gastric and renal safety |
| |
| Authors: | M. Pairet L. Churchill G. Trummlitz G. Engelhardt |
| |
| Affiliation: | (1) Department of Biological Research, Boehringer Ingelheim Research Laboratories, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany;(2) Department of Inflammatory Disease, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA |
| |
| Abstract: | The discovery of an inducible isoform of cyclooxygenase (COX-2) requires a refinement of the theory that inhibition of cyclooxygenase activity is responsible for both therapeutic and side-effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Pharmacological results with developmental compounds suggest that COX-2 is the relevant target for the therapeutic (i.e. anti-inflammatory) effects of NSAIDs, whereas gastric and renal side-effects are related to inhibition of constitutive COX-1. However a role of COX-1 in inflammation cannot be excluded. Furthermore, more research effort is needed to investigate the functional relevance of COX-2 in normal tissue. |
| |
| Keywords: | COX-1 COX-2 NSAIDs |
| 本文献已被 SpringerLink 等数据库收录！ |
|
